Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.

Authors

S. Hegewisch-Becker

Private Practice of Oncology, Hamburg, Germany

S. Hegewisch-Becker , C. A. Lerchenmuller , A. Welt , T. Decker , M. Just , C. Steffens , A. Hipper , N. Marschner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC—A single-arm, multicenter, phase Ⅱ clinical trial.

First Author: Jin Yan

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

First Author: Christoph Rochlitz

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.

First Author: Hideaki Bando

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

First Author: Christophe Tournigand